Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells

Leukemia
P de FabritiisB Calabretta

Abstract

We studied the effect of phosphorothioate oligodeoxynucleotides ([S]ODNs) complementary to the bcr-abl junction on cells taken at diagnosis from 41 patients with Philadelphia-positive chronic myelogenous leukaemia (CML). Experiments included the evaluation of the anti-leukaemic effect of 16- and 26-mer antisense [S]ODNs on both mononuclear and CD34+ cells, evaluation of incubation time and correlation of colony growth inhibition with the down-regulation of p210(bcr-abl). At the same time, the uptake of [S]ODNs by mononuclear and purified CD34+ cell populations and the cross-hybridization of 26- and 16-mer [S]ODNs with the complementary sequences were evaluated. After incubation for 120 h with 26-mer antisense [S]ODNs on mononuclear cells, overall mean colony recovery was 41.9% of the untreated control samples; in particular, a significant reduction in colony formation was observed in 22 of the 35 cases tested. The effect of 26-mer ODNs on CD34+ cells was comparable to that observed on mononuclear cells in terms of colony inhibition; however, a higher proportion of cases showed a significant inhibition of colony formation. In comparison with the 26-mer antisense [S]ODNs, the anti-leukaemic effect of the 16-mer antisense [S]ODNs ...Continue Reading

Citations

May 12, 2000·Biochimica Et Biophysica Acta·N Agarwal, A M Gewirtz
May 30, 2001·Experimental Hematology·B N JahagirdarC M Verfaillie
Oct 18, 2003·Seminars in Cancer Biology·Christine Damm-WelkArndt Borkhardt
Apr 28, 2000·Leukemia & Lymphoma·A PigneuxJ Reiffers
Mar 21, 2002·Expert Opinion on Therapeutic Targets·T KindlerT Fischer
Nov 4, 2000·Expert Opinion on Investigational Drugs·P Maslak, D Scheinberg
Oct 9, 2002·Oncogene·Shanhai XieRalph B Arlinghaus
May 29, 2002·Oncogene·Charles C ReedRenato V Iozzo
Apr 20, 2004·Oncogene·Danilo Perrotti, Bruno Calabretta
Jun 19, 2003·Oncogene·Michal Oskar NowickiTomasz Skorski
Jul 9, 2002·Oncogene·Derrick S GrantRenato V Iozzo
Jul 4, 2002·Oncogene·Malgorzata KorusIan P Whitehead
Aug 12, 2003·Oncogene·Umberto GalderisiAntonio Giordano
Aug 30, 2003·Oncogene·Usha Kasid, Anatoly Dritschilo
Jun 13, 2000·Oncogene·P J CofferR P de Groot
Jun 13, 2000·Oncogene·N N Danial, P Rothman
Jun 13, 2000·Oncogene·T BowmanR Jove
Oct 19, 2001·Oncogene·S Wong, O N Witte
Aug 30, 2000·Oncogene·M Nieborowska-SkorskaT Skorski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.